Evidence-Based Medicine: The Design and Interpretation of Noninferiority Clinical Trials in Veterinary Medicine

被引:21
作者
Freise, K. J. [1 ]
Lin, T. -L. [1 ]
Fan, T. M. [2 ]
Recta, V. [3 ]
Clark, T. P. [1 ]
机构
[1] Nexcyon Pharmaceut Inc, Madison, WI 53703 USA
[2] Univ Illinois, Coll Vet Med, Urbana, IL 61801 USA
[3] US FDA, Ctr Vet Med, Rockville, MD 20857 USA
关键词
Ethics; Placebo; Positive control; Statistical methods; PLACEBO-CONTROLLED TRIALS; ACTIVE-CONTROL TRIALS; NON-INFERIORITY; ACUTE PAIN; MUSCULOSKELETAL DISORDERS; CANINE OSTEOARTHRITIS; ORAL ROBENACOXIB; MELOXICAM; EFFICACY; DOGS;
D O I
10.1111/jvim.12211
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Noninferiority trials are clinical studies designed to demonstrate that an investigational drug is at least as effective as an established treatment within a predetermined margin. They are conducted, in part, because of ethical concerns of administering a placebo to veterinary patients when an established effective treatment exists. The use of noninferiority trial designs has become more common in veterinary medicine with the increasing number of established veterinary therapeutics and the desire to eliminate potential pain or distress in a placebo-controlled study. Selecting the appropriate active control and an a priori noninferiority margin between the investigational and active control drug are unique and critical design factors for noninferiority studies. Without reliable historical knowledge of the disease response in the absence of treatment and of the response to the selected active control drug, proper design and interpretation of a noninferiority trial is not possible. Despite the appeal of conducting noninferiority trials to eliminate ethical concerns of placebo-controlled studies, there are real limitations and possible ethical conundrums associated with noninferiority trials. The consequences of incorrect study conclusions because of poor noninferiority trial design need careful attention. Alternative trial designs to typical noninferiority studies exist, but these too have limitations and must also be carefully considered.
引用
收藏
页码:1305 / 1317
页数:13
相关论文
共 67 条
[1]   STATISTICS NOTES - ABSENCE OF EVIDENCE IS NOT EVIDENCE OF ABSENCE [J].
ALTMAN, DG ;
BLAND, JM .
BRITISH MEDICAL JOURNAL, 1995, 311 (7003) :485-485
[2]   Field evaluations of the efficacy and safety of emodepside plus toltrazuril (Procox® oral suspension for dogs) against naturally acquired nematode and Isospora spp. infections in dogs [J].
Altreuther G. ;
Gasda N. ;
Adler K. ;
Hellmann K. ;
Thurieau H. ;
Schimmel A. ;
Hutchens D. ;
Krieger K.J. .
Parasitology Research, 2011, 109 (Suppl 1) :S21-S28
[3]   Field Evaluation of the Efficacy and Safety of Emodepside plus Praziquantel Tablets (Profender® Tablets for Dogs) against Naturally Acquired Nematode and Cestode Infections in Dogs [J].
Altreuther, Gertraut ;
Radeloff, Isabelle ;
LeSueur, Christophe ;
Schimmel, Annette ;
Krieger, Klemens J. .
PARASITOLOGY RESEARCH, 2009, 105 :S23-S29
[4]  
[Anonymous], 2000, POINTS CONS SWITCH S
[5]  
[Anonymous], GUID CHOIC NON MARG
[6]  
[Anonymous], 2010, TESTING STAT HYPOTHE, DOI DOI 10.1201/EBK1439808184
[7]  
[Anonymous], GUID IND NON CLIN TR
[8]  
[Anonymous], [No title captured]
[9]   Randomized noninferiority clinical trial evaluating 3 commercial dry cow mastitis preparations: I. Quarter-level outcomes [J].
Arruda, A. G. ;
Godden, S. ;
Rapnicki, P. ;
Gorden, P. ;
Timms, L. ;
Aly, S. S. ;
Lehenbauer, T. W. ;
Champagne, J. .
JOURNAL OF DAIRY SCIENCE, 2013, 96 (07) :4419-4435
[10]  
Bayer HealthCare LLC. Freedom of Information (FOI) Summary, 2007, 141275 NADA BAYER HE